A Phase 3 interventional study of olanzapine and amantadine in Schizophrenia and Schizoaffective Disorders, sponsored by Eli Lilly and Company. Completed at 15 sites in 7 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2009-10-06.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 97 studies testing olanzapine in Schizophrenia — 2 open to participants now, 3 under way, 1 of them phase 3. Olanzapine · Schizophrenia.
Among the 97 studies testing olanzapine in Schizophrenia, this one is the 34th largest by enrollment of the 94 interventional ones that give a count, is one of 9 that started in 2006, is one of 25 in phase 3, and was the 43rd registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →2 of the 97 studies testing olanzapine in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:
Minerva Neurosciences · Sites in United States
Ages 18–55
Centre for Addiction and Mental Health · Sites in Canada
Ages 18+
By country, each count listing its studies:
Olanzapine: first FDA approval 1996 (ZYPREXA), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
97 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 8 · Phase 3 25 · Phase 4 46
First in 1997; this study’s year is marked. 9 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 199 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 114 across the 94 interventional studies. Of the 86 that completed or were terminated, 25 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 97 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
33 studies in Schizophrenia by Eli Lilly and Company: 2 open now, 2 under way, none of them phase 3. Of 31 finished, 9 (29%) have results posted.
Among the 33 studies in Schizophrenia by Eli Lilly and Company, this one is the 16th largest by enrollment of the 29 interventional ones that give a count, is one of 6 that started in 2006, is one of 10 in phase 3, and was the 22nd registered.
Eli Lilly and Company’s Schizophrenia studies by the year they started, since 2001.
2 of the studies testing olanzapine in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03781115University of ArizonaProposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia | 2027-02-10 |
| NCT04478838Centre for Addiction and Mental Health"Extended" (Alternate Day) Antipsychotic Dosing | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 97 studies testing olanzapine in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 33 in Schizophrenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this study is to answer the following questions:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
olanzapine plus behavioral information
Drug: olanzapine · Behavioral: Wellness education
Olanzapine and Pharmacological Algorithm 1a - amantadine first plus behavioral information
Drug: olanzapine · Drug: amantadine · Drug: metformin · Drug: zonisamide · Behavioral: Wellness education
Olanzapine and Pharmacological Algorithm 1b - metformin first plus behavioral information
Drug: olanzapine · Drug: amantadine · Drug: metformin · Drug: zonisamide · Behavioral: Wellness education
5-20 milligrams (mg), oral, daily for 22 weeks.
Also known as: LY170053, Zyprexa
Amantadine, 100 milligrams (mg), oral, 1 twice a day (BID). Patients who gained greater than 3 kilograms (kg) will switch to metformin. Patients who gained greater than 3 kg after switching to metformin will be switched to zonisamide.
Metformin, 500 mg, oral, twice a day (BID) for 2 weeks titrated to 500mg three times a day (TID) thereafter. Patients who gain greater than 3 kilograms (kg) will be switched to amantadine. Patients who gained greater than 3 kg after switching to amantadine will be switched to zonisamide.
Zonisamide, 100-400mg, oral, daily.
weight management
Change From Baseline to Endpoint in Weight
Time frame: Baseline to endpoint (22 weeks)
Mean Change From Baseline to Endpoint in Fasting Triglycerides
Time frame: Baseline to endpoint (22 weeks)
Mean Change From Baseline to Endpoint in Fasting Total Cholesterol
Time frame: Baseline to endpoint (22 weeks)
Mean Change From Baseline to Endpoint in Fasting High Density Lipoprotein (HDL) Cholesterol
Time frame: Baseline to endpoint (22 weeks)
Mean Change From Baseline to Endpoint in Fasting Low Density Lipoprotein (LDL) Cholesterol
Time frame: Baseline to endpoint (22 weeks)
Mean Change From Baseline to Endpoint in Fasting Glucose
Time frame: Baseline to endpoint (22 weeks)
Mean Change From Baseline to Endpoint in Hemoglobin A1c
Time frame: Baseline to endpoint (22 weeks)
Change From Baseline to Endpoint in Brief Psychiatric Rating Scale (BPRS) Total Score
The BPRS is an 18-item clinician-administered scale used to assess the degree of severity of a subject's general psychopathological symptoms. Each item is rated on a scale from 1 (symptom not present) to 7 (symptom extremely severe). The BPRS total score ranges from 18 to 126.
Time frame: Baseline to endpoint (22 weeks)
Change From Baseline to Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).
Time frame: Baseline to endpoint (22 weeks)
Change From Baseline to Endpoint in Clinical Global Impression - Severity Scale (CGI-S)
Measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).
Time frame: Baseline to endpoint (22 weeks)
Correlations Between Weight Changes and Changes in Eating Inventory (EI) and Food Craving Inventory (FCI) at 2 Weeks and 22 Weeks
To understand the drivers of weight gain as indicated by the correlation between weight changes and changes in the Eating Inventory (EI) and Food Craving Inventory (FCI). The EI is a 51-item inventory that measures dietary restraint, disinhibition, and perceived hunger. The FCI is a 28-item instrument measuring the frequency over the past month of general cravings and cravings for specific types of foods, namely: high fats, sweets, carbohydrates/starches, and fast-food fats. Correlations were computed on the combined treatment groups.
Time frame: Baseline to endpoint (22 weeks)
| Milestone | Olanzapine | Olanzapine + Amantadine | Olanzapine + Metformin |
|---|---|---|---|
| Started | 50 | 76 | 73 |
| Completed | 39 | 50 | 50 |
| Not completed | 11 | 26 | 23 |
| Withdrew: Adverse event | 2 | 8 | 4 |
| Withdrew: Clinical relapse | 0 | 1 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 3 |
| Withdrew: Lost to follow-up | 2 | 2 | 2 |
| Withdrew: Physician decision | 2 | 0 | 1 |
| Withdrew: Protocol violation | 1 | 2 | 3 |
| Withdrew: Sponsor decision | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 4 | 12 | 9 |
| kilograms | Olanzapine | Olanzapine + Amantadine | Olanzapine + Metformin |
|---|---|---|---|
| Change From Baseline to Endpoint in Weight | 2.76 ± 0.75 | 2.40 ± 0.65 | 0.65 ± 0.63 |
| millimoles per Liter (mmol/L) | Olanzapine | Olanzapine + Amantadine | Olanzapine + Metformin |
|---|---|---|---|
| Baseline | 1.58 ± 0.81 | 1.61 ± 0.76 | 1.68 ± 1.00 |
| Change from Baseline | 0.33 ± 1.01 | 0.35 ± 0.88 | 0.06 ± 0.64 |
| millimole per Liter (mmol/L) | Olanzapine | Olanzapine + Amantadine | Olanzapine + Metformin |
|---|---|---|---|
| Baseline | 5.01 ± 1.00 | 5.03 ± 1.09 | 4.91 ± 1.21 |
| Change from Baseline | 0.36 ± 0.84 | 0.01 ± 1.06 | -0.08 ± 0.92 |
| millimole per liter (mmol/L) | Olanzapine | Olanzapine + Amantadine | Olanzapine + Metformin |
|---|---|---|---|
| Baseline | 1.25 ± 0.29 | 1.26 ± 0.36 | 1.22 ± 0.35 |
| Change from Baseline | -0.00 ± 0.23 | -0.11 ± 0.25 | -0.08 ± 0.24 |
| millimole per Liter (mmol/L) | Olanzapine | Olanzapine + Amantadine | Olanzapine + Metformin |
|---|---|---|---|
| Baseline | 3.02 ± 0.88 | 3.06 ± 1.03 | 2.91 ± 0.93 |
| Change from Baseline | 0.16 ± 0.60 | -0.04 ± 0.95 | -0.02 ± 0.84 |
| millimole per Liter (mmol/L) | Olanzapine | Olanzapine + Amantadine | Olanzapine + Metformin |
|---|---|---|---|
| Baseline | 5.32 ± 0.46 | 5.25 ± 0.78 | 5.28 ± 0.63 |
| Change from Baseline | 0.26 ± 0.99 | 0.10 ± 0.48 | 0.01 ± 0.58 |
| percent hemoglobin A1c | Olanzapine | Olanzapine + Amantadine | Olanzapine + Metformin |
|---|---|---|---|
| Baseline | 5.51 ± 0.46 | 5.48 ± 0.39 | 5.53 ± 0.37 |
| Change from Baseline | 0.09 ± 0.45 | 0.10 ± 0.37 | -0.03 ± 0.25 |
The BPRS is an 18-item clinician-administered scale used to assess the degree of severity of a subject's general psychopathological symptoms. Each item is rated on a scale from 1 (symptom not present) to 7 (symptom extremely severe). The BPRS total score ranges from 18 to 126.
| units on a scale | Olanzapine | Olanzapine + Amantadine | Olanzapine + Metformin |
|---|---|---|---|
| Baseline | 48.24 ± 15.98 | 45.90 ± 12.44 | 47.00 ± 14.18 |
| Change from Baseline | -13.89 ± 18.61 | -9.90 ± 11.24 | -9.72 ± 14.15 |
The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).
| units on a scale | Olanzapine | Olanzapine + Amantadine | Olanzapine + Metformin |
|---|---|---|---|
| Baseline | 12.76 ± 8.08 | 14.22 ± 11.14 | 15.40 ± 9.21 |
| Change from Baseline | -6.39 ± 8.37 | -4.12 ± 7.20 | -4.36 ± 7.47 |
Measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).
| units on a scale | Olanzapine | Olanzapine + Amantadine | Olanzapine + Metformin |
|---|---|---|---|
| Baseline | 4.06 ± 1.24 | 4.03 ± 1.07 | 4.00 ± 1.13 |
| Change from Baseline | -0.98 ± 1.13 | -0.72 ± 1.14 | -0.79 ± 1.03 |
To understand the drivers of weight gain as indicated by the correlation between weight changes and changes in the Eating Inventory (EI) and Food Craving Inventory (FCI). The EI is a 51-item inventory that measures dietary restraint, disinhibition, and perceived hunger. The FCI is a 28-item instrument measuring the frequency over the past month of general cravings and cravings for specific types of foods, namely: high fats, sweets, carbohydrates/starches, and fast-food fats. Correlations were computed on the combined treatment groups.
| correlation | 2 Weeks | 22 Weeks |
|---|---|---|
| EI: Disinhibition | -0.034 | 0.285 |
| EI: Cognitive Restraint | -0.273 | -0.038 |
| EI: Hunger | -0.150 | 0.148 |
| FCI: Carbohydrates/Starches (N=186, N=141) | 0.013 | -0.064 |
| FCI: Fast Food Fats (N=188, N=140) | -0.019 | 0.047 |
| FCI: High Fats (N=186, N=138) | 0.051 | 0.043 |
| FCI: Sweets (N=187, N=140) | 0.022 | -0.008 |
| FCI: Total Score (N=184, N=137) | 0.039 | -0.000 |
Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Olanzapine | — | — | — |
| Olanzapine + Amantadine | — | — | — |
| Olanzapine + Metformin | — | — | — |
| Event | Olanzapine | Olanzapine + Amantadine | Olanzapine + Metformin |
|---|---|---|---|
| SchizophreniaPsychiatric disorders | 3/50 | 0/76 | 0/73 |
| HallucinationPsychiatric disorders | 0/50 | 1/76 | 2/73 |
| Psychotic disorderPsychiatric disorders | 1/50 | 0/76 | 0/73 |
| Suicidal ideationPsychiatric disorders | 1/50 | 0/76 | 0/73 |
| Chest painGeneral disorders | 0/50 | 0/76 | 1/73 |
| Suicide attemptPsychiatric disorders | 0/50 | 0/76 | 1/73 |
| Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/50 | 1/76 | 0/73 |
| AkathisiaNervous system disorders | 0/50 | 1/76 | 0/73 |
| Panic attackPsychiatric disorders | 0/50 | 1/76 | 0/73 |
| Event | Olanzapine | Olanzapine + Amantadine | Olanzapine + Metformin |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/50 | 3/76 | 10/73 |
| SomnolenceNervous system disorders | 4/50 | 5/76 | 8/73 |
| InsomniaPsychiatric disorders | 5/50 | 4/76 | 1/73 |
| NauseaGastrointestinal disorders | 2/50 | 3/76 | 5/73 |
| VomitingGastrointestinal disorders | 0/50 | 1/76 | 5/73 |
| Increased appetiteMetabolism and nutrition disorders | 3/50 | 1/76 | 3/73 |
| Weight increasedInvestigations | 2/50 | 4/76 | 4/73 |
| HeadacheNervous system disorders | 2/50 | 2/76 | 4/73 |
| Dry mouthGastrointestinal disorders | 2/50 | 4/76 | 0/73 |
| NasopharyngitisInfections and infestations | 0/50 | 4/76 | 0/73 |
| Age Continuous(years) | Olanzapine | Olanzapine + Amantadine | Olanzapine + Metformin | Total |
|---|---|---|---|---|
| Mean | 38.7 ± 12.89 | 38.2 ± 11.40 | 38.7 ± 12.01 | 38.5 ± 11.95 |
| Sex: Female, Male(Participants) | Olanzapine | Olanzapine + Amantadine | Olanzapine + Metformin | Total |
|---|---|---|---|---|
| Female | 19 | 30 | 30 | 79 |
| Male | 31 | 46 | 43 | 120 |
| Region of Enrollment(participants) | Olanzapine | Olanzapine + Amantadine | Olanzapine + Metformin | Total |
|---|---|---|---|---|
| United States | 13 | 22 | 21 | 56 |
| Mexico | 7 | 9 | 11 | 27 |
| Puerto Rico | 5 | 8 | 5 | 18 |
| Israel | 5 | 8 | 9 | 22 |
| Russian Federation | 11 | 15 | 14 | 40 |
| Korea, Republic of | 9 | 14 | 13 | 36 |
| Race/Ethnicity(participants) | Olanzapine | Olanzapine + Amantadine | Olanzapine + Metformin | Total |
|---|---|---|---|---|
| African | 2 | 10 | 4 | 16 |
| Caucasian | 23 | 30 | 34 | 87 |
| East Asian | 10 | 15 | 14 | 39 |
| Hispanic | 14 | 20 | 18 | 52 |
| Native American | 0 | 0 | 1 | 1 |
| West Asian | 1 | 1 | 2 | 4 |
| Type of Diagnosis(participants) | Olanzapine | Olanzapine + Amantadine | Olanzapine + Metformin | Total |
|---|---|---|---|---|
| Schizoaffective | 8 | 15 | 18 | 41 |
| Schizophrenia | 42 | 61 | 55 | 158 |
| Body Mass Index (BMI)(kilograms/square meter (kg/m^2)) | Olanzapine | Olanzapine + Amantadine | Olanzapine + Metformin | Total |
|---|---|---|---|---|
| Mean | 27.0 ± 4.53 | 27.3 ± 4.67 | 27.0 ± 4.84 | 27.1 ± 4.68 |
| Onset Age(years) | Olanzapine | Olanzapine + Amantadine | Olanzapine + Metformin | Total |
|---|---|---|---|---|
| Mean | 24.35 ± 8.42 | 26.44 ± 9.98 | 24.40 ± 9.18 | 25.15 ± 9.32 |
| Previous Number of Episodes(number of episodes) | Olanzapine | Olanzapine + Amantadine | Olanzapine + Metformin | Total |
|---|---|---|---|---|
| Mean | 1.53 ± 1.02 | 2.19 ± 5.90 | 2.22 ± 5.77 | 2.04 ± 5.06 |
1 further baseline measures are reported on the registry.
The record gives a start of Nov 2006, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2009, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olanzapine